Hemolysis and Vaso-Occlusive Crisis in Sickle Cell Disease: A Review

Year 2025, Volume: 7 Issue: 4, -

Amjad Mahmood Qadir , Abdalla Hama

https://doi.org/10.46310/tjim.1667957

Abstract

Sickle Cell Disease (SCD) is an inherited condition characterised by haemolysis and Vaso-occlusive crisis (VOC), resulting in considerable morbidity and organ impairment. These crises lead to consequences like stroke, splenic sequestration, and acute chest syndrome, significantly affecting patients quality of life. This review combines information on hemolysis and Vaso-occlusive crises in sickle cell disease, highlighting their aetiology, clinical implications, and prospective treatment approaches to alleviate disease severity.
A systematic review was performed using PRISMA principles. Relevant publications from PubMed, Google Scholar, Web of Science, Scopus, and ScienceDirect were examined, focusing on research published between 2000 and 2024. A total of 68 research articles were included. Haemolysis in sickle cell disease leads to oxidative stress, endothelial dysfunction, and an increased risk of thrombosis. Volatile organic compounds (VOCs) exacerbate these effects, resulting in persistent discomfort, multi-organ impairment, and an increased healthcare burden. Although hydroxyurea remains a fundamental treatment, novel therapies, including voxelotor, crizanlizumab, and gene therapy, exhibit potential. Moreover, antioxidant supplementation, encompassing vitamins D, A, E, and C, has shown promise in mitigating oxidative damage, but clinical results are variable.
Hemolysis and Vaso-occlusive crises are pivotal to the pathophysiology of sickle cell disease, substantially exacerbating consequences and patient distress. Progress in pharmacological and supportive therapy provides optimism for enhanced management. Further study is necessary to determine long-term effectiveness and accessibility.

Keywords

Sickle Cell Disease , Vaso-occlusive Crisis , Haemolysis , Antioxidants , Gene Therapy

References

• Chung SM AA, Russell MO. Management of osteonecrosis in sickle-cell, 1978:158-74. aaigvCORR.
• Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF: Sickle cell disease. Nature reviews Disease primers.(2018).4(1):1-22. doi.org/10.1038/nrdp.2018.10
• Serjeant GR: The natural history of sickle cell disease. Cold Spring Harbor perspectives in medicine.(2013).3(10):a011783. doi: 10.1101/cshperspect.a011783
• Steinberg MH: Genetic etiologies for phenotypic diversity in sickle cell anemia. The Scientific World Journal.(2009).9(1):46-67. doi.org/10.1100/tsw.2009.10
• Steinberg MH, Sebastiani P: Genetic modifiers of sickle cell disease. American journal of hematology.(2012).87(8):795-803. doi.org/10.1002/ajh.23232
• Rees DC, Williams TN, Gladwin MT: Sickle-cell disease. The Lancet.(2010).376(9757):2018-2031. DOI: 10.1016/S0140-6736(10)61029-X
• Lee MT, Licursi M, McMahon DJ: Vitamin D deficiency and acute vaso‐occlusive complications in children with sickle cell disease. Pediatric Blood & Cancer.(2015).62(4):643-647. doi.org/10.1002/pbc.25399
• Silva Junior GBd, Daher EDF, Rocha FACd: Osteoarticular involvement in sickle cell disease. Revista brasileira de hematologia e hemoterapia.(2012).34:156-164. doi.org/10.5581/1516-8484.20120036
• Ballas SK, Darbari DS: Review/overview of pain in sickle cell disease. Complementary therapies in medicine.(2020).49:102327. doi.org/10.1016/j.ctim.2020.102327
• Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN: Global burden of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, excess mortality, and interventions. PLoS medicine.(2013).10(7):e1001484. doi.org/10.1371/journal.pmed.1001484
• Bonham VL, Smilan LE: Somatic genome editing in sickle cell disease: rewriting a more just future. NCL Rev.(2018).97:1093.
• Alderson P: The Politics of Childhoods Real and Imagined: Practical application of critical realism and childhood studies, vol. 2: Routledge; 2015. doi.org/10.4324/9781315669380
• Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM, Sickle Cell Disease tCSo: Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood, The Journal of the American Society of Hematology.(1998).91(1):288-294. doi.org/10.1182/blood.V91.1.288
• Kiriza N: A Comprehensive Review of Sickle Cell Disease Treatment and Research Centers in the United States and Their Implication on Healthcare Access. University of Pittsburgh; 2021.
• Naik RP, Streiff MB, Haywood Jr C, Segal JB, Lanzkron S: Venous thromboembolism incidence in the cooperative study of sickle cell disease. Journal of Thrombosis and Haemostasis.(2014).12(12):2010-2016. doi.org/10.1111/jth.12744
• Brunson A, Lei A, Rosenberg AS, White RH, Keegan T, Wun T: Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality. British journal of haematology.(2017).178(2):319-326. doi.org/10.1111/bjh.14655
• Lizarralde-Iragorri MA, Shet AS: Sickle cell disease: a paradigm for venous thrombosis pathophysiology. International journal of molecular sciences.(2020).21(15):5279. doi.org/10.3390/ijms21155279
• Ashwell E: The basics of blood and associated disorders. British Journal of Nursing.(2022).31(21):1096-1102. doi.org/10.12968/bjon.2022.31.21.1096
• Obeagu EI: Influence of Hemoglobin Variants on Vaso-Occlusive Phenomena in Sickle Cell Anemia: A Review. International Journal of Medical Sciences and Pharma Research.(2024).10(2):54-59. doi.org/10.22270/ijmspr.v10i2.104
• Alnaqbi KA: A Rare Case of Multiple Bone Infarctions and Abnormal Pulmonary Function Tests in a Patient With Compound Heterozygous Hemoglobin S and Type 2 Hereditary Persistence of Fetal Hemoglobin. Cureus.(2024).16(8). DOI: 10.7759/cureus.66395
• Nelson M, Noisette L, Pugh N, Gordeuk V, Hsu L, Wun T, Shah N, Glassberg J, Kutlar A, Hankins J: The clinical spectrum of HbSC sickle cell disease‐not a benign condition. British Journal of Haematology.(2024).205(2):653-663. doi.org/10.1111/bjh.19523
• Mian UK, Tang J, Allende AP, Heo M, Bernstein N, Vattappally L, Schoenfeld D, Minniti CP: Elevated fetal haemoglobin levels are associated with decreased incidence of retinopathy in adults with sickle cell disease. British journal of haematology.(2018).183(5):807-811. doi.org/10.1111/bjh.15617
• Sathi BK, Yoshida Y, Weaver MR, Nolan LS, Gruner B, Balasa V, Altes T, Leiva-Salinas C: Unusually high prevalence of stroke and cerebral vasculopathy in hemoglobin SC Disease: a Retrospective Single Institution Study. Acta Haematologica.(2022).145(2):160-169. doi.org/10.1159/000519360
• Petigas L, Seck N, Doupa D, Diagne I, Roth-Kleiner M: Findings supporting neonatal screening for sickle cell disease: an observational study in Senegal. Frontiers in pediatrics.(2025).13:1578570. doi.org/10.3389/fped.2025.1578570
• Jeremiah Z, Neenwi EM: Expression of major haemoglobin haplotypes in the first twenty-four months of life suggests a gradual decline of normal haemoglobin A among infants of African descent. Medicinska istraživanja.(2025).58(1). doi.org/10.5937/medi58-52808
• Kohne E: Hemoglobinopathies: clinical manifestations, diagnosis, and treatment. Deutsches Ärzteblatt International.(2011).108(31-32):532. doi: 10.3238/arztebl.2011.0532
• Uçucu S, Karabıyık T, Azik F: Difficulties in the diagnosis of HbS/beta thalassemia: Really a mild disease? Journal of Medical Biochemistry.(2022).41(1):32. doi: 10.5937/jomb0-30420
• Adams RJ, Kutlar A, McKie V, Carl E, Nichols FT, Liu JC, McKie K, Clary A: Alpha thalassemia and stroke risk in sickle cell anemia. American journal of hematology.(1994).45(4):279-282. doi.org/10.1002/ajh.2830450402
• Ataga KI, Gordeuk VR, Agodoa I, Colby JA, Gittings K, Allen IE: Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: A systematic literature review and meta-analysis. PLoS One.(2020).15(4):e0229959. doi.org/10.1371/journal.pone.0229959
• Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT: Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. New England Journal of Medicine.(1998).339(1):5-11. DOI: 10.1056/NEJM199807023390102
• Hebbel RP, Eaton J, Balasingam M, Steinberg MH: Spontaneous oxygen radical generation by sickle erythrocytes. The Journal of clinical investigation.(1982).70(6):1253-1259. doi.org/10.1172/JCI110724.
• Hebbel RP, Morgan WT, Eaton JW, Hedlund BE: Accelerated autoxidation and heme loss due to instability of sickle hemoglobin. Proceedings of the National Academy of Sciences.(1988).85(1):237-241. doi.org/10.1073/pnas.85.1.237
• Kanias T, Acker JP: Biopreservation of red blood cells–the struggle with hemoglobin oxidation. The FEBS journal.(2010).277(2):343-356. doi.org/10.1111/j.1742-4658.2009.07472.x
• Srivastava NK, Mukherjee S, Mishra VN: One advantageous reflection of iron metabolism in context of normal physiology and pathological phases. Clinical Nutrition ESPEN.(2023). doi.org/10.1016/j.clnesp.2023.10.006
• Alayash AI: Oxidative pathways in the sickle cell and beyond. Blood Cells, Molecules, and Diseases.(2018).70:78-86. doi.org/10.1016/j.bcmd.2017.05.009
• Demirci-Cekic S, Özkan G, Avan AN, Uzunboy S, Çapanoğlu E, Apak R: Biomarkers of oxidative stress and antioxidant defense. Journal of pharmaceutical and biomedical analysis.(2022).209:114477. doi.org/10.1016/j.jpba.2021.114477
• Pisoschi AM, Pop A: The role of antioxidants in the chemistry of oxidative stress: A review. European journal of medicinal chemistry.(2015).97:55-74. doi.org/10.1016/j.ejmech.2015.04.040
• Azzi A: The role of α-tocopherol in preventing disease. European journal of nutrition.(2004).43:i18-i25. doi.org/10.1007/s00394-004-1105-7
• Esterbauer H, Dieber-Rotheneder M, Striegl G, Waeg G: Role of vitamin E in preventing the oxidation of low-density lipoprotein. The American journal of clinical nutrition.(1991).53(1):S314-S321. DOI: 10.1093/ajcn/53.1.314S
• Berridge MJ: Vitamin D cell signalling in health and disease. Biochemical and biophysical research communications.(2015).460(1):53-71. doi.org/10.1016/j.bbrc.2015.01.008
• Liu Y, Hyde AS, Simpson MA, Barycki JJ: Emerging regulatory paradigms in glutathione metabolism. Advances in cancer research.(2014).122:69-101. doi.org/10.1016/B978-0-12-420117-0.00002-5
• Vašková J, Kočan L, Vaško L, Perjési P: Glutathione-Related Enzymes and Proteins: A Review. Molecules.(2023).28(3):1447. doi.org/10.3390/molecules28031447
• Liu X, Zhang Y, Zhuang L, Olszewski K, Gan B: NADPH debt drives redox bankruptcy: SLC7A11/xCT-mediated cystine uptake as a double-edged sword in cellular redox regulation. Genes & diseases.(2021).8(6):731-745. doi.org/10.1016/j.gendis.2020.11.010
• Gammoh NZ, Rink L: Zinc in infection and inflammation. Nutrients.(2017).9(6):624. doi.org/10.3390/nu9060624
• Pisoschi AM, Iordache F, Stanca L, Gajaila I, Ghimpeteanu OM, Geicu OI, Bilteanu L, Serban AI: Antioxidant, anti-inflammatory, and immunomodulatory roles of nonvitamin antioxidants in anti-SARS-CoV-2 therapy. Journal of Medicinal Chemistry.(2022).65(19):12562-12593. doi.org/10.1021/acs.jmedchem.2c01134
• Hama AH, Shakiba E, Rahimi Z, Karimi M, Mozafari H, Abdulkarim OA: Vitamin D level, lipid profile, and vitamin D receptor and transporter gene variants in sickle cell disease patients from Kurdistan of Iraq. Journal of clinical laboratory analysis.(2021).35(9):e23908. doi.org/10.1002/jcla.23908
• Singh P, Shukla AK, Behera SK, Tiwari PK: Zinc application enhances superoxide dismutase and carbonic anhydrase activities in zinc-efficient and zinc-inefficient wheat genotypes. Journal of Soil Science and Plant Nutrition.(2019).19:477-487.
• Yalcinkaya A, Unal S, Oztas Y: Altered HDL particle in sickle cell disease: decreased cholesterol content is associated with hemolysis, whereas decreased Apolipoprotein A1 is linked to inflammation. Lipids in health and disease.(2019).18:1-7.
• Serjeant GR, Ceulaer CD, Lethbridge R, Morris J, And AS, Thomas PW: The painful crisis of homozygous sickle cell disease: clinical features. British journal of haematology.(1994).87(3):586-591. doi.org/10.1111/j.1365-2141.1994.tb08317.x
• PETERSDORF RG, BEESON PB: Fever of unexplained origin: report on 100 cases. Medicine.(1961).40(1):1-30.
• Bainbridge R, Higgs DR, Maude GH, Serjeant GR: Clinical presentation of homozygous sickle cell disease. The Journal of pediatrics.(1985).106(6):881-885. doi.org/10.1016/S0022-3476(85)80230-4
• Onalo R: Cardiovascular changes in sickle cell crises and impact of arginine supplementation in vaso-occlusive crisis and acute chest syndrome. Faculty of Health Sciences, University of the Witwatersrand, Johannesburg; 2020.
• Michaels LA, Maraventano MF, Drachtman RA: Thrombosis and gangrene in a patient with sickle cell disease and dactylitis. The Journal of pediatrics.(2003).142(4):449. DOI: 10.1067/mpd.2003.102
• Santos LFOd, Guimarães MW, Baptista AF, Sá KN: Impact of neuropathic pain on quality of life in adults with sickle cell disease: observational study. Hematology, Transfusion and Cell Therapy.(2021).43:263-267. doi.org/10.1016/j.htct.2020.03.010
• Takaoka K, Cyril AC, Jinesh S, Radhakrishnan R: Mechanisms of pain in sickle cell disease. British Journal of Pain.(2021).15(2):213-220. doi.org/10.1177/2049463720920682
• Hama AH, Qadir AM: Detection of Sickle Cell Disease in Kurdistan, Iraq. doi.org/10.1007/s00192-017-3536-8. DOI:10.48309/IJABBR.2025.2035372.1525
• Berghmans B: Physiotherapy for pelvic pain and female sexual dysfunction: an untapped resource. International urogynecology journal.(2018).29:631-638. doi.org/10.1007/s00192-017-3536-8
• Kassim MAK, Pantazi AC, Nori W, Tuta LA, Balasa AL, Mihai CM, Mihai L, Frecus CE, Lupu VV, Lupu A: Non-pharmacological interventions for pain management in hemodialysis: a narrative review. Journal of Clinical Medicine.(2023).12(16):5390. doi.org/10.3390/jcm12165390
• Lorente L, Vera M, Peiró T: Nurses stressors and psychological distress during the COVID‐19 pandemic: The mediating role of coping and resilience. Journal of advanced nursing.(2021).77(3):1335-1344. doi.org/10.1111/jan.14695
• Berzon R, Hays R, Shumaker S: International use, application and performance of health-related quality of life instruments. Quality of Life Research.(1993).2(6):367-368. doi.org/10.1007/BF00422214
• Yawn BP, John-Sowah J: Management of sickle cell disease: recommendations from the 2014 expert panel report. American family physician.(2015).92(12):1069-1076.
• Palm N, Floroff C, Hassig TB, Boylan A, Kanter J: Low-dose ketamine infusion for adjunct management during vaso-occlusive episodes in adults with sickle cell disease: a case series. Journal of pain & palliative care pharmacotherapy.(2018).32(1):20-26. doi.org/10.1080/15360288.2018.1468383
• Brandow AM, Panepinto JA: Clinical interpretation of quantitative sensory testing as a measure of pain sensitivity in patients with sickle cell disease. Journal of pediatric hematology/oncology.(2016).38(4):288. DOI: 10.1097/MPH.0000000000000532
• Darbari DS, Sheehan VA, Ballas SK: The vaso‐occlusive pain crisis in sickle cell disease: definition, pathophysiology, and management. European journal of haematology.(2020).105(3):237-246. doi.org/10.1111/ejh.13430
• Edwards CL, Scales MT, Loughlin C, Bennett GG, Harris-Peterson S, Castro LMD, Whitworth E, Abrams M, Feliu M, Johnson S: A brief review of the pathophysiology, associated pain, and psychosocial issues in sickle cell disease. International journal of behavioral medicine.(2005).12:171-179. doi.org/10.1207/s15327558ijbm1203_6
• Pope M, Albo C, Kidwell KM, Xu H, Bowman L, Wells L, Barrett N, Fields S, Bora P, Clay ELJ: Evolution of chronic pain in sickle cell disease. Blood.(2016).128(22):1297. doi.org/10.1182/blood.V128.22.1297.1297
• Tawfic QA, Faris AS, Kausalya R: The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease. Journal of pain and symptom management.(2014).47(2):334-340. doi.org/10.1016/j.jpainsymman.2013.03.012
• Neri CM, Pestieau SR, Darbari DS: Low‐dose ketamine as a potential adjuvant therapy for painful vaso‐occlusive crises in sickle cell disease. Pediatric Anesthesia.(2013).23(8):684-689. doi.org/10.1111/pan.12172
• Anie KA, Green J: Psychological therapies for sickle cell disease and pain. Cochrane Database of Systematic Reviews.(2015).(5). doi.org/10.1002/14651858.CD001916
• Shah N, Bhor M, Xie L, Paulose J, Yuce H: Medical resource use and costs of treating sickle cell-related vaso-occlusive crisis episodes: a retrospective claims study. Journal of health economics and outcomes research.(2020).7(1):52. doi: 10.36469/jheor.2020.12852
• Shapiro BS, Dinges DF, Orne EC, Bauer N, Reilly LB, Whitehouse WG, Ohene-Frempong K, Orne MT: Home management of sickle cell-related pain in children and adolescents: natural history and impact on school attendance. Pain.(1995).61(1):139-144. doi.org/10.1016/0304-3959(94)00164-A
• Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, Roberts JD, Dahman B, Aisiku IP, Levenson JL, Roseff SD: Daily assessment of pain in adults with sickle cell disease. Annals of internal medicine.(2008).148(2):94-101. doi.org/10.7326/0003-4819-148-2-200801150-00004
• Holdford D, Vendetti N, Sop DM, Johnson S, Smith WR: Indirect economic burden of sickle cell disease. Value in Health.(2021).24(8):1095-1101. doi.org/10.1016/j.jval.2021.02.014
• Mvundura M, Amendah D, Kavanagh PL, Sprinz PG, Grosse SD: Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States. Pediatric blood & cancer.(2009).53(4):642-646. doi.org/10.1002/pbc.22069
• Kanter J, Kruse-Jarres R: Management of sickle cell disease from childhood through adulthood. Blood reviews.(2013).27(6):279-287. doi.org/10.1016/j.blre.2013.09.001
• Kapur A: Economic analysis of diabetes care. Indian Journal of Medical Research.(2007).125(3):473-482.
• Kauf TL, Coates TD, Huazhi L, Mody‐Patel N, Hartzema AG: The cost of health care for children and adults with sickle cell disease. American journal of hematology.(2009).84(6):323-327. doi.org/10.1002/ajh.21408
• Kumar A, Avishay DM, Jones CR, Shaikh JD, Kaur R, Aljadah M, Kichloo A, Shiwalkar N, Keshavamurthy S: Sudden cardiac death: epidemiology, pathogenesis and management. Reviews in Cardiovascular Medicine.(2021).22(1):147-158. DOI: 10.31083/j.rcm.2021.01.207
• Sethi S: Approaches to Anti Infective Therapies. Bentham Sci.(2021).5:120. doi.org/10.2174/97898149983901210501
• Chou ST: Transfusion therapy for sickle cell disease: a balancing act. Hematology 2013, the American Society of Hematology Education Program Book.(2013).2013(1):439-446. doi.org/10.1182/asheducation-2013.1.439
• Kutlar A, Kanter J, Liles DK, Alvarez OA, Cançado RD, Friedrisch JR, Knight‐Madden JM, Bruederle A, Shi M, Zhu Z: Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis. American journal of hematology.(2019).94(1):55-61. doi.org/10.1002/ajh.25308
• Simeone JC, Shah S, Ganz ML, Sullivan S, Koralova A, LeGrand J, Bushman J: Healthcare resource utilization and cost among patients with type 1 diabetes in the United States. Journal of Managed Care & Specialty Pharmacy.(2020).26(11):1399-1410. doi.org/10.18553/jmcp.2020.26.11.139
• Smith WR, Scherer M: Sickle-cell pain: advances in epidemiology and etiology. Hematology 2010, the American Society of Hematology Education Program Book.(2010).2010(1):409-415. doi.org/10.1182/asheducation-2010.1.409
• Gueguen A, Mahevas M, Nzouakou R, Hosseini H, Habibi A, Bachir D, Brugière P, Lionnet F, Ribeil JA, Godeau B: Sickle‐cell disease stroke throughout life: A retrospective study in an adult referral center. American Journal of Hematology.(2014).89(3):267-272. doi.org/10.1002/ajh.23625
• Adams RJ, McKie VC, Brambilla D, Carl E, Gallagher D, Nichols FT, Roach S, Abboud M, Berman B, Driscoll C: Stroke prevention trial in sickle cell anemia. Controlled clinical trials.(1998).19(1):110-129. doi.org/10.1002/ajh.23625
• Oluwole O, Brunson AM, Adesina OO, Willen SM, Keegan TH, Fertrin KY, Wun T: Rates of strokes in Californians with sickle cell disease in the post-STOP era. Blood.(2024).144(24):2517-2527. doi.org/10.1182/blood.2023023031
• Fox CK, Leykina L, Hills NK, Kwiatkowski JL, Kanter J, Strouse JJ, Voeks JH, Fullerton HJ, Adams RJ, Group P-SS: Hemorrhagic stroke in children and adults with sickle cell anemia: the Post-STOP Cohort. Stroke.(2022).53(11):e463-e466. doi.org/10.1161/STROKEAHA.122.038651
• Bolarinwa AB, Oduwole O, Okebe J, Ogbenna AA, Otokiti OE, Olatinwo AT: Antioxidant supplementation for sickle cell disease. Cochrane Database of Systematic Reviews.(2024).(5). doi.org/10.1161/STROKEAHA.122.038651
• Delesderrier E, Curioni C, Omena J, Macedo CR, Cople-Rodrigues C, Citelli M: Antioxidant nutrients and hemolysis in sickle cell disease. Clinica Chimica Acta.(2020).510:381-390. doi.org/10.1016/j.cca.2020.07.020
• Ibrahim A, Muhammad SA: Antioxidant-rich nutraceutical as a therapeutic strategy for sickle cell disease. Journal of the american nutrition association.(2023).42(6):588-597. doi.org/10.1080/27697061.2022.2108930
• Alabi OJ, Adegboyega FN, Olawoyin DS, Babatunde OA: Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases. Heliyon.(2022).8(6). DOI: 10.1016/j.heliyon.2022.e09630
• Huang H-Y, Appel LJ, Croft KD, Miller III ER, Mori TA, Puddey IB: Effects of vitamin C and vitamin E on in vivo lipid peroxidation: results of a randomized controlled trial. The American journal of clinical nutrition.(2002).76(3):549-555. doi.org/10.1093/ajcn/76.3.549
• Arruda MM, Mecabo G, Rodrigues CA, Matsuda SS, Rabelo IB, Figueiredo MS: Antioxidant vitamins C and E supplementation increases markers of haemolysis in sickle cell anaemia patients: a randomized, double‐blind, placebo‐controlled trial. British journal of haematology.(2013).160(5):688-700. doi.org/10.1111/bjh.12185
• Wang S-W, Zhang X-W, Qu J-X, Rao Y-Z, Lu S, Wang B, He J, Zhao Y, Rao B-Q: Hemolysis attributed to high dose vitamin C: Two case reports. World Journal of Clinical Cases.(2024).12(17):3168. doi: 10.12998/wjcc.v12.i17.3168
• Evans VA, O’Neill LA: Lessons from Glucocorticoids, Metformin, and Dimethyl Fumarate: Could Targeting Immunometabolism Lead to Better Anti-Inflammatory Therapies? Annual Review of Pharmacology and Toxicology.(2025).66. doi.org/10.1146/annurev-pharmtox-062624-013520
• Luo M, Zhou L, Huang Z, Li B, Nice EC, Xu J, Huang C: Antioxidant therapy in cancer: rationale and progress. Antioxidants.(2022).11(6):1128. doi.org/10.3390/antiox11061128
• Manivasagam T, Arunadevi S, Essa MM, SaravanaBabu C, Borah A, Thenmozhi AJ, Qoronfleh MW: Role of oxidative stress and antioxidants in autism. Personalized food intervention and therapy for autism spectrum disorder management.(2020).193-206. doi.org/10.1007/978-3-030-30402-7_7
• Hsu T-J, Hsieh R-H, Huang C-H, Chen C-S, Lin W-Y, Huang Y-C, Lin J-H, Huang K-T, Liu Y-L, Tsai H-M: Efficacy of zinc supplementation in the management of primary dysmenorrhea: A systematic review and meta-analysis. Nutrients.(2024).16(23):4116. doi: 10.3390/nu16234116
• Veljović M, Mihajlović I, Subota V, Antunović M, Jevđić J, Udovičić I, Popadić A, Vulović T: Effect of pretreatment with omega-3 polyunsaturated fatty acids (PUFAs) on hematological parameters and platelets aggregation in patients during elective coronary artery bypass grafting. Vojnosanitetski pregled.(2013).70(4):396-402. doi.org/10.2298/VSP1304396V
• Doaei S, Gholami S, Rastgoo S, Gholamalizadeh M, Bourbour F, Bagheri SE, Samipoor F, Akbari ME, Shadnoush M, Ghorat F: The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial. Journal of translational medicine.(2021).19(1):128. doi.org/10.1186/s12967-021-02795-5
• Gharekhani A, Khatami M-R, Dashti-Khavidaki S, Razeghi E, Abdollahi A, Hashemi-Nazari S-S, Mansournia M-A: Potential effects of omega-3 fatty acids on anemia and inflammatory markers in maintenance hemodialysis patients. DARU Journal of Pharmaceutical Sciences.(2014).22(1):11. doi.org/10.1186/2008-2231-22-11
• Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR, Anemia IotMSoHiSC: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New England Journal of Medicine.(1995).332(20):1317-1322. DOI: 10.1056/NEJM199505183322001
• Nevitt SJ, Jones AP, Howard J: Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database of Systematic Reviews.(2017).(4). doi.org/10.1002/14651858.CD002202.pub2
• Rankine-Mullings AE, Nevitt SJ: Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database of Systematic Reviews.(2022).(9). doi.org/10.1002/14651858.CD002202.pub3
• Goldberg MA, Brugnara C, Dover GJ, Schapira L, Charache S, Bunn HF: Treatment of sickle cell anemia with hydroxyurea and erythropoietin. New England Journal of Medicine.(1990).323(6):366-372. DOI: 10.1056/NEJM199008093230602
• López Rubio M, Argüello Marina M: The Current Role of Hydroxyurea in the Treatment of Sickle Cell Anemia. Journal of Clinical Medicine.(2024).13(21):6404. doi.org/10.3390/jcm13216404
• Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L: The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: a 17.5 year follow‐up. American journal of hematology.(2010).85(6):403-408. doi.org/10.1002/ajh.21699
• Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC: A phase 3 randomized trial of voxelotor in sickle cell disease. New England Journal of Medicine.(2019).381(6):509-519. DOI: 10.1056/NEJMoa1903212
• Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S: Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Haematology.(2021).8(5):e323-e333. DOI: 10.1016/S2352-3026(21)00059-4
• Estepp JH, Kalpatthi R, Woods G, Trompeter S, Liem RI, Sims K, Inati A, Inusa BP, Campbell A, Piccone C: Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years. Pediatric blood & cancer.(2022).69(8):e29716. doi.org/10.1002/pbc.29716
• White SL, Hart K, Kohn DB: Diverse approaches to gene therapy of sickle cell disease. Annual review of medicine.(2023).74(1):473-487. doi.org/10.1146/annurev-med-042921-021707
• Esrick EB, Bauer DE: Genetic therapies for sickle cell disease. In: Seminars in Hematology: 2018. Elsevier: 76-86. doi.org/10.1053/j.seminhematol.2018.04.014
• Ballantine J, Tisdale JF: Gene Therapy for Sickle Cell Disease: Recent Advances, Clinical Trials, and Future directions. Cytotherapy.(2024). doi.org/10.1016/j.jcyt.2024.11.006
• Alshammari S: Sickle cell disease associated lipid changes and their relevance towards the disease pathogenesis And Lipid Biomarkers and Embryo Quality in In Vitro Fertilization; Pregnancy Success Differentially Expressed by Body Weight. 2021). doi.org/10.25772/FNS0-X122
• Almashjary MN: The Impact of Dietary Iron Restriction on Sickling Kinetics and Hemolysis in a Transgenic Model of Sickle Cell Disease: The Catholic University of America; 2020.
• Glaros AK, Razvi R, Shah N, Zaidi AU: Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor. Therapeutic advances in hematology.(2021).12:20406207211001136. doi.org/10.1177/20406207211001
• Ikawa Y, Miccio A, Magrin E, Kwiatkowski JL, Rivella S, Cavazzana M: Gene therapy of hemoglobinopathies: progress and future challenges. Human Molecular Genetics.(2019).28(R1):R24-R30. doi.org/10.1093/hmg/ddz172
• Salcedo J, Bulovic J, Young CM: Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease. Scientific Reports.(2021).11(1):10838. doi.org/10.1038/s41598-021-90405-1
• Nader E, Romana M, Connes P: The red blood cell—inflammation vicious circle in sickle cell disease. Frontiers in immunology.(2020).11:454. doi.org/10.3389/fimmu.2020.00454
• Jagadeeswaran R, Rivers A: Evolving treatment paradigms in sickle cell disease. Hematology 2014, the American Society of Hematology Education Program Book.(2017).2017(1):440-446. doi.org/10.1182/asheducation-2017.1.440
• Vona R, Sposi NM, Mattia L, Gambardella L, Straface E, Pietraforte D: Sickle cell disease: role of oxidative stress and antioxidant therapy. Antioxidants.(2021).10(2):296. doi.org/10.3390/antiox10020296
• Treadwell MJ, Du L, Bhasin N, Marsh AM, Wun T, Bender M, Wong TE, Crook N, Chung JH, Norman S: Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: report from a US regional collaborative. Frontiers in genetics.(2022).13:921432. doi.org/10.3389/fgene.2022.921432
• Abraham AA, Tisdale JF: Gene therapy for sickle cell disease: moving from the bench to the bedside. Blood, The Journal of the American Society of Hematology.(2021).138(11):932-941. doi.org/10.1182/blood.2019003776